Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Next Previous
Trial Profile

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizotinib (Primary) ; Iobenguane (Primary) ; Busulfan; Carboplatin; Cisplatin; Cyclophosphamide; Dexrazoxane; Dinutuximab; Doxorubicin; Etoposide; Etoposide phosphate; Isotretinoin; Melphalan; Sargramostim; Thiotepa; Topotecan; Vincristine
  • Indications Neuroblastoma
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 02 Oct 2023 Status changed from recruiting to active, no longer recruiting.
  • 06 Jun 2023 Results (n=360; As of December 31, 2022) assessing the preliminary feasibility and acceptability of the first COG trial to prospectively embed SDOH data collection, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 25 Apr 2023 Planned number of patients changed from 813 to 724.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top